Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

Eda Tanrikulu Simsek; Ahmet Emre Eskazan; Mahir Cengiz; Muhlis Cem Ar; Seda Ekizoglu; Ayse Salihoglu; Emine Gulturk; Tugrul Elverdi; Seniz Ongoren Aydin; Ahu Senem Demiroz; Ayse Nur Buyru; Zafer Baslar; Ugur Ozbek; Burhan Ferhanoglu; Yildiz Aydin; Nukhet Tuzuner; Teoman Soysal

doi:10.1136/jclinpath-2015-203320

Article info

Original article

Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

Authors

Eda Tanrikulu Simsek Division of Medical Oncology, Department of Internal Medicine, Pendik Training and Research Hospital, Marmara University, Istanbul, Turkey PubMed articles Google scholar articles
Ahmet Emre Eskazan Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles
Mahir Cengiz Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles
Muhlis Cem Ar Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles
Seda Ekizoglu Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles
Ayse Salihoglu Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles
Emine Gulturk Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles
Tugrul Elverdi Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles
Seniz Ongoren Aydin Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles
Ahu Senem Demiroz Department of Pathology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles
Ayse Nur Buyru Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles
Zafer Baslar Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles
Ugur Ozbek Department of Genetics, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles
Burhan Ferhanoglu Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Koc University, Istanbul, Turkey PubMed articles Google scholar articles
Yildiz Aydin Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles
Nukhet Tuzuner Department of Pathology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles
Teoman Soysal Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey PubMed articles Google scholar articles

Correspondence to Dr Teoman Soysal, Division of Hematology, Department of Internal Medicine, Istanbul University, Cerrahpasa Faculty of Medicine, Fatih, Istanbul 34303, Turkey; teomansoysal{at}gmail.com

View Full Text

Citation

Tanrikulu Simsek E, Eskazan AE, Cengiz M, et al

Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

Journal of Clinical Pathology 2016;69:810-816.

Publication history

Received August 7, 2015
Revised December 4, 2015
Accepted December 23, 2015
First published January 25, 2016.

Online issue publication

July 08, 2020

Article Versions

Previous version (8 July 2020).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password